a public good project by the
Synthesis
Company
of California

© 2026

Hisaki Fujii | doi.page

0 works0 citations0 h-index

Hisaki Fujii

Astellas Pharma (United States)(US)

Publications by Year

Research Areas

Acute Lymphoblastic Leukemia research, Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, Multiple Myeloma Research and Treatments, Immune Cell Function and Interaction

Most-Cited Works

→ A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer(2015)270 cited
→ Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group(2007)146 cited
→ Pregnancy outcomes following gabapentin use(2013)101 cited
→ Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor‐related neurotoxicity after hematopoietic stem cell transplantation(2009)69 cited
→ Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma(2020)65 cited
→ Significant Transplantation-Related Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem Cell Transplantation(2015)60 cited

→ Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer(2017)

50 cited

→ In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides(2006)42 cited

→ N-(4-Hydroxyphenyl)retinamide (4-HPR) Induces Leukemia Cell Death via Generation of Reactive Oxygen Species(2003)34 cited

→ Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations.(2023)32 cited